Companies sponsors |
AstraZeneca (acalabrutinib) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
African Caribbean Leukaemia Trust |
|
Anthony Nolan |
|
Black Health Agency for Equality |
|
Blood Cancer UK |
|
Cancer Black Care |
|
Cancer Equality |
|
Cancer52 |
|
DKMS |
|
Helen Rollason Cancer Charity |
|
Independent Cancer Patients Voice |
|
Kevin Karawa Leukaemia Trust |
|
Leukaemia Cancer Society |
|
Leukaemia Care |
|
Leukaemia UK |
|
Lymphoma Action |
|
Macmillan Cancer Support |
|
Maggie’s Centres |
|
Marie Curie |
|
South Asian Health Foundation |
|
Specialised Healthcare Alliance |
|
Tenovus Cancer Care |
|
WMUK |
Professional groups |
Association of Cancer Physicians |
|
British Geriatrics Society |
|
British Institute of Radiology |
|
British Oncology Pharmacy Association |
|
British Psychosocial Oncology Society |
|
British Society for Haematology |
|
British Society of Interventional Radiology |
|
British Transplantation Society |
|
Cancer Research UK |
|
NHS Blood and Transplant |
|
Royal College of General Practitioners |
|
Royal College of Nursing |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
|
Royal Pharmaceutical Society |
|
Royal Society of Medicine |
|
Society of Radiographers |
|
UK Clinical Pharmacy Association |
|
UK Oncology Nursing Society |
|
United Kingdom Cutaneous Lymphoma Group |
Associated public health groups |
Public Health Wales |
|
UK Health Security Agency |
Comparator companies |
Accord-UK Ltd (bendamustine) |
|
Aspire Pharma (bortezomib) |
|
Aurobindo Pharma (bortezomib) |
|
Baxter Healthcare Ltd (cyclophosphamide, doxorubicin) |
|
Biotech Pharma (bortezomib) |
|
Celltrion Healthcare UK Ltd (rituximab) |
|
Dr Reddy’s Laboratories UK Ltd (bendamustine, bortezomib) |
|
Hospira UK Ltd (cytarabine, vincristine) |
|
Jazz Pharmaceuticals UK (cytarabine) |
|
Johnson & Johnson Ltd (bortezomib) |
|
medac GmbH (bortezomib, doxorubicin) |
|
MSN Laboratories Europe (bortezomib) |
|
Mylan (bortezomib) |
|
Pfizer Ltd (bortezomib, doxorubicin, rituximab) |
|
Roche Products Ltd (rituximab) |
|
Sandoz Ltd (bortezomib, cyclophosphamide, rituximab) |
|
Seacross Pharmaceuticals Ltd (bendamustine, doxorubicin) |
|
Sun Pharma (bortezomib) |
|
Thornton & Ross Ltd (bortezomib) |
|
Tillomed Laboratories Ltd (bortezomib) |
|
Zentiva Pharma Ltd (bendamustine) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
Allied Health Professionals Federation |
|
Board of Community Health Councils in Wales |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health - Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
National Association of Primary Care |
|
National Pharmacy Association |
|
NHS Confederation |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Cochrane Haematological Malignancies Group |
|
Cochrane UK |
|
Genomics England |
|
Institute of Cancer Research |
|
Leukaemia Busters |
|
Lymphoma Research Trust |
|
MRC Clinical Trials Unit |
|
National Institute for Health Research |